

# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

VE

APPLICATION NO				VO
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOOLGET HE
09/015,078	01/29/98	SUERBAUM		ATTORNEY DOCKET NO.
			5	2356-0073-01

HM12/0616 SXAMINER
FINNEGAN HENDERSON FARABOW
GARRETT AND DUNNER
1300 I STREET N W
WASHINGTON DC 20005-3315

ARTUNIT PAPER NUMBER
1645

DATE MAILED: 06/16/99

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No.

Applicant(s)

09/015,078

Examiner

Sharon L. Turner, Ph.D.

Group Art Unit 1645

Suerbaum

Responsive to communication(s) filed on <u>1-29-98</u> This action is <b>FINAL</b> .	
- The detail is I have.	•
☐ Since this application is in condition for allowance except for forma in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D.	
A shortened statutory period for response to this action is set to expire is longer, from the mailing date of this communication. Failure to respapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	e1 month(s), or thirty days, whichever
Disposition of Claims	
X Claim(s) 31-42	io/oro populita de un
Of the above, claim(s)	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
	is/are rejected.
	is/are objected to.
ar	re subject to restriction or election requirement.
-Priodition Fupers	
☐ See the attached Notice of Draftsperson's Patent Drawing Review	v, PTO-948.
☐ The drawing(s) filed on is/are objected to by	v the Evamines
☐ The proposed drawing correction, filed onis	s approved disapproved.
☐ The specification is objected to by the Examiner.	Siddphoved.
$\square$ The oath or declaration is objected to by the Examiner.	
riority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under 35	5 U.S.C. & 119/a)_/d/
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the prio	ority documents have been
received in Application No. (Series Code/Serial Number)	<u>.</u>
received in this national stage application from the Internation	Onal Bureau (PCT Bula 17 2/2)
continued copies not received:	
Acknowledgement is made of a claim for domestic priority under 3	35 U.S.C. § 119(e)
ttachment(s)	1000,
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)	
The interview Summary, PTO-413	
<ul><li>☐ Notice of Draftsperson's Patent Drawing Review, PTO-948</li><li>☐ Notice of Informal Patent Application, PTO-152</li></ul>	
1   MOTION of Information   District   1   1   1   1   1   1   1   1   1	

#### **DETAILED ACTION**

#### Sequence Compliance

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

#### Election/Restriction

- 2. Claims 1-30 are canceled. Claims 31-42 are pending.
- 3. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 31-36 drawn to a DNA probe, classified in class 536, subclass 23.1.
  - II. Claims 37-42, drawn to a method of identifying infection, classified in class 435,subclass 6.
- 4. The inventions are distinct, each from the other because of the following reasons:
- 5. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case (1) the process of identifying infection could be practiced with biological samples and antibodies, and (2) the nucleic acids of Group I can be used in the Polymerase Chain Reaction (PCR).

6. This application contains claims directed to the following patentably distinct species of the claimed invention: Group I, (a) OFL1bA-1 and (b) OFL1bA-2. Group II, (a) a bacterial strain lacking the hook protein of H. pylori, (b) strain N6 (NCIMB 40512), (c) strain N6 (NCIMB 40512) and lacking the hook protein, (d) strain N6flbA- (NCIMB 40747), (e) N6flbA- (NCIMB 40747) and lacking the hook protein.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 31-32 and 37-38 are generic. The applicant should elect one species of both group I and group II, and should elect an invention of group I or group II.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 8. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group III, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

### Time Period for Response

- 10. The time period for response for both the Sequence Requirements and the Restriction/Election is set to run concurrently. A complete response should respond to both the Sequence Requirements and the Restriction/Election.
- 11. APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under

the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

12. Any inquiry of a general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1600 is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon L. Turner, Ph.D. whose telephone number is (703) 308-0056. The examiner can normally be reached on Monday-Friday from 6:30 AM to 3:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (703) 308-3995.

Sharon L. Turner, Ph.D. June 10, 1999

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600